All GlaxoSmithKline (GSK) articles
-
NewsGSK acquires food allergy firm Rapt Therapeutics for $2.2bn
Will gain access to ozureprubart, a potential best-in-class antibody for food allergies, and expand its respiratory, immunology and inflammation pipeline.
-
NewsSamsung gains first US manufacturing site through $280m GSK deal
The CDMO will acquire the pharma company’s Human Genome Sciences facility in Maryland.
-
NewsPhase III data for next-gen green inhaler push GSK closer to Net Zero targets
New findings support use of salbutamol MDI formulation in the next-generation low carbon propellant as a more sustainable option for patients with respiratory disease.
-
NewsGSK’s Emma Walmsley to step down as CEO
In a surprise announcement, she will be replaced at the UK pharma company by its Chief Commercial Officer Luke Miels.
-
NewsGSK outlines $30bn, five-year plan for R&D and manufacturing in the US
The company’s investment strategy will also encompass AI, digital technology and supply chain infrastructure.
-
NewsGSK ultra-long-acting biologic shows Phase III potential
The treatment, being evaluated for severe asthma, is the first ultra-long-acting biologic to be evaluated in Phase III trials.
-
NewsHow can AI be best harnessed for pharmacovigilance data?
A GSK-funded paper on pharmacovigilance stated that the pharma industry needs to harness the properties of data to allow optimal use of AI, otherwise "we will fail to do all we can for patient safety".
-
ArticleAccelerating drug development
Here, Dave Elder explores how a ‘quick-approval, quick-withdrawal from the market’ approach is used to accelerate drug development.